Director

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Institution	Shares	Value	Change
Robeco Institutional Asset Management B.V	460,602	$287M	INCREASED
Assenagon Asset Management	244,927	$153M	INCREASED
Mcdonald Capital Investors Inc	193,038	$120M	DECREASED
Swedbank AB	189,848	$118M	DECREASED
Retirement Systems of Alabama	127,869	$80M	DECREASED

Insider	Type	Shares	Value	Date
Arthur F Ryan (Director)	SELL	200	$130K	2026-07-02
Arthur F Ryan (Director)	SELL	1	$712	2026-05-01
Arthur F Ryan (Director)	SELL	2	$1K	2026-05-01
Arthur F Ryan (Director)	SELL	6	$4K	2026-05-01
Arthur F Ryan (Director)	SELL	4	$3K	2026-05-01

Member	Type	Amount	Date
Alan Armstrong (Republican)	PURCHASE	$1,001 - $15,000	2026-03-27
Gilbert Cisneros (Democrat)	SALE	$1,001 - $15,000	2026-05-15
Ro Khanna (Democrat)	PURCHASE	$1,001 - $15,000	2026-04-13

Regeneron Pharmaceuticals Inc (REGN) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades